COMPANY

History

Innovative R&D strategies for sustainable growth

Innovative drug development
for the healthy life of humanity

  • 2022-2024

    Biomarker-driven anti-cancer therapy development

    • 2024

      • 03
        • Evaluation of Anti-cancer efficacy of ED2 ADCs
      • 02
        • Establishment of manufacturing and analysis methods for ED2 ADCs
      • 01
        • Evaluation of Anti-cancer efficacy of ED1 lead antibodies in animal models

    • 2023

      • 12
        • Establishment of a characterization and evaluation system for effective ED2 antibodies
      • 09
        • Securing effective ED2 antibodies and establishing a manufacturing process protocol
      • 05
        • Selection of 'the Baby Unicorn 200 companies'
      • 03
        • Evaluation of the anticancer efficacy of ED1 effective antibodies in metastatic animal models
      • 02
        • Discovery of new ED3 targets and establishment of therapeutic development strategies
      • 01
        • MOU Signed for New Drug Research and Development with the Ulsan University Institute of Digestive Disease

    • 2022

      • 11
        • Securing ED1 Effective Antibodies and Establishing Manufacturing Process
      • 08
        • Securing effective ED2 antibodies and establishing a manufacturing process protocol
      • 04
        • Expansion of New Drug Development Research Personnel
      • 02
        • Intensification of Antibody New Drug Development: Establishment of a Research Institute Branch

  • 2020-2021

    Licensing Medical Device,
    Clinical Research,
    Patent Registration

    • 2021

      • 12
        • Pre-A Series Investment Attraction
      • 07
        • Patent Applications of 'specific antibody for colorectal cancer' in the United States, Europe, and China
      • 06
        • Asan Medical Center Selected for Research-Focused Hospital Project
        • participating company for Healthcare Data Center Hospital
      • 05
        • Patent Registration of 'specific peptide for colorectal cancer'

    • 2020

      • 09
        • Registered the patent for therapeutic diagnostic and therapeutic antibody of colon cancer
      • 07
        • Colon cancer metastasis and inflammatory colitis animal model construction
      • 04
        • Certified KGMP for medical endoscopy
        • Manufacturing Declaration for Medical Image Processing Device (M-Imaging 001)
      • 03
        • Manufacturing Certification for Endosco light source device (M-System 001)
        • Manufacturing Certification for Endosco light source device (M-Probe 001)

  • 2016-2019

    Medical Device Development &
    Research Services

    • 2019

      • 11
        • Development of colorectal cancer contrast agents
        • KGMP certification for diagnostic medical equipment
      • 07
        • Seed Funding Attraction
      • 06
        • Discovery of biomarker probes for colorectal cancer
      • 05
        • Establishment of a GMP branch
      • 03
        • Venture Company Certification
      • 02
        • Registered the Trademark for M-ChESS

    • 2018

      • 12
        • Selected as a startup growth project by the Ministry of SMEs and Startups (Fluorescent contrast agent development)
        • Medical device manufacturing license (Ministry of Food and Drug Safety No.6319)

    • 2017

      • 09
        • License in 'endoscopy instruments and devices'
      • 06
        • Acquired Grant from Startup Support Center
      • 04
        • Affiliated research institute certification
        • New drug development bioimaging service
      • 03
        • License in 'human colorectal-specific binding peptide'
      • 01
        • Selected as a participating enterprise for development of 'Smart convergent endoscopy' (The Ministry of Trade, Industry and Energy)

    • 2016

      • 10
        • Establishment of EdisBiotech
닫기